home contact company.overview news sitemap print


NMI-TT Contact Person

Markwiesenstr. 55
72770 Reutlingen

Ion Channel


page: 1 of 9 | items: 1 to 3 | next

Register for the 6th Global RPPA Meeting in Reutlingen
Come to Reutlingen, and hear about the latest advances in Reverse Phase Protein Arrays (RPPAs) and their application for biomarker research.

Sentinel Oncology and NMI TT Pharmaservices awarded Eurostars grant for development of a novel biomarker for treatment of Fragile X Syndrome

Cambridge/UK and Berlin/Germany, May 2, 2016 – Sentinel Oncology
and NMI TT Pharmaservices today announced that they have received grant funding for the development of a companion diagnostic to compliment the ongoing drug development activities within Sentinel Oncology for the treatment of the Fragile X Syndrome (FXS), a genetically inherited orphan disease that manifests itself in intellectual disability, for which no treatments are currently available. [more...]

Product Launch: new Cav1.2 cell line
Cav1.2 ion channels are expressed in heart, smooth muscle and neurons, and therefore are therapeutic targets in cardiac arrhythmia and hypertension.



NMI TT a business unit of NMI